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Abstract
Background—Caffeine is a widely consumed psychoactive stimulant and is of epidemiological 
interest. Major sources of caffeine are challenging to standardize, and the use of biomarkers has 
been proposed as an alternative means of assessing intake.
Objective—We described urine caffeine and caffeine metabolite concentrations (n = 2466) and 
excretion rates (n = 2261) in the U.S. population ≥6 y by age, sex, race-ethnicity and caffeine 
intake (from foods, beverages and dietary supplements).
Methods—We measured caffeine and 14 of its metabolites in spot urine samples from the cross- 
sectional NHANES 2009–2010 by use of liquid chromatography-tandem mass spectrometry.
Results—Caffeine and its metabolites were detectable in the urine of most persons, generally at 
concentrations ≥1 μmol/L. Median concentrations (95% CI) ranged from 0.560 (0.497–0.620) 
μmol/L to 58.6 (48.6–67.2) μmol/L; median excretion rates from 0.423 (0.385–0.468) nmol/min to 
46.0 (40.7–50.2) nmol/min. Urine concentrations and excretion rates for 9 analytes (caffeine, 
theophylline, paraxanthine, 1-methylxanthine, 1-methyluric acid, 1,3-dimethyluric acid, 1,7- 
dimethyluric acid, 1,3,7-trimethyluric acid, and 5-acetylamino-6-amino-3-methyluracil) had 
moderate correlations with caffeine intake (Spearman |r| 0.55–0.68, P <0.0001); the remaining 
analytes had low correlations (|r| 0.15–0.33, P <0.0001). We observed larger differences in 
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geometric mean concentrations and excretion rates between the highest vs. lowest quartiles of 
caffeine intake for these 9 compounds compared to the rest. Consistent with dietary caffeine 
intake, we observed that urine concentrations and excretion rates for most compounds were 
significantly (P <0.05) higher in males vs. females, non-Hispanic whites vs. Hispanics and non- 
Hispanic blacks, and highest in persons aged 40–59 y.
Conclusion—Excretion of caffeine and its metabolites in urine was common in the U.S. 
population. Based on the observed associations between spot urine concentrations or excretion 
rates with caffeine intake, several of these compounds show promise as potential biomarkers of 
caffeine intake.
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Introduction
Caffeine is the most widely consumed psychoactive substance in the world. In 2009–2010, 
average dietary caffeine consumption in U.S. adults was >200 mg/day. Approximately 35% 
dietary caffeine was consumed away from home, with 43% consumed outside of any defined 
meal (1). Although caffeine intake in U.S. adults and children has remained relatively 
unchanged from 1999 to 2010, some changes in sources have been observed. In children and 
adolescents, the relative dietary contribution of caffeine from sodas has decreased (62% to 
38%) whereas coffee has increased (from 10% to 24%) and “energy” drinks have emerged 
as a conspicuous source (non-existent to 6%) (2). Caffeine continues to be a dietary 
compound of public health interest. Recent meta-analyses have examined the association of 
caffeine intake with diseases and conditions such as breast cancer (3) and atrial fibrillation 
(4), and associations with positive health outcomes have been observed in some cases, such 
as with Parkinson’s disease (5). Caffeine consumption is generally considered to be safe; 
however, fatalities due to apparent caffeine intoxication (6), as well as associations of 
adverse health events with caffeinated “energy” drinks (7) have been reported.
Assessment of caffeine exposure in epidemiological studies has been done almost 
exclusively using dietary intake data. Accurately establishing the caffeine content of dietary 
sources can be challenging (8) and efforts to improve the quality of dietary intake data 
methods are ongoing (9). The possibility of using caffeine and caffeine metabolites as 
biomarkers of intake has been explored in a limited number of settings. Crews et al. (10) 
examined the relationship of caffeine dose to the concentration of caffeine and several 
caffeine metabolites in 24-hour urine samples in 8 subjects of known cytochrome P450 1A2 
(CYP1A2) phenotype. Grosso et al. (11) studied the relationship between urine (n = 98–263) 
and umbilical cord blood (n = 455–1609) concentrations of caffeine, paraxanthine, 
theophylline and theobromine, and self-reported caffeine intake in pregnant women. 
Klebanoff et al. (12) looked at serum caffeine and paraxanthine concentrations in relation to 
caffeine intake in 239 pregnant women. In addition to their use as intake biomarkers, urine 
caffeine and its metabolites have been used for phenotyping CYP1A2 (13) and N-
acetyltransferase-2 (14) activity in population-based settings.
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To the best of our knowledge, no representative population based studies of biologic levels 
of caffeine and caffeine metabolites and their relationship with caffeine intake exist. The 
objective of our study was to describe urine concentrations and excretion rates of caffeine 
and its metabolites in the U.S. population ≥6 y, by age, sex, race-ethnicity and caffeine 
intake. The NHANES 2009–2010 data provide the first nationally representative description 
of urine caffeine and caffeine metabolite concentrations and excretion rates measured in spot 
urine samples, and a preliminary evaluation of their potential use as biomarkers of caffeine 
intake.
Subjects and Methods
Study design and subjects
The NHANES is a cross-sectional survey on the health and nutritional status of the civilian 
non-institutionalized U.S. population conducted by the CDC National Center for Health 
Statistics (NCHS) (15). The survey makes use of a stratified, multistage, probability sample 
designed to represent the U.S. population on the basis of age, sex, and race-ethnicity. 
Demographic participant characteristics, dietary supplement use, and health-related data are 
obtained during a home interview; a physical examination, the collection of blood and urine 
samples, and other assessments such as dietary intake, are performed in a mobile 
examination center (MEC). All respondents gave their informed consent, and the NHANES 
protocol was reviewed and approved by the NCHS Research Ethics Review Board. Interview 
and examination response rates for each survey period are publically available (16).
Urine collection and storage
Spot urine specimens were collected from all NHANES participants from the 2009–2010 
survey cycle ≥6 y of age who were able to provide a specimen. Each participant was 
instructed to provide a urine sample as soon as possible upon entry to the MEC, and to 
completely empty their bladder when providing the sample. The date, time, and volume of 
urine collection were recorded. Urine specimens were then allocated into aliquots for the 
various urine specimen assays to be performed; for caffeine and caffeine metabolites, a 1-
mL aliquot of urine in a 2-mL polypropylene cryovial was created from a random 1/3 subset 
of NHANES participants (n = 2831) (17). Samples were frozen immediately after processing 
and shipped on dry ice to the CDC on a weekly basis. Samples were stored at ≤−70°C until 
analysis (18).
Laboratory methods
Urine samples were analyzed for caffeine and caffeine metabolites by use of liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) with electrospray ionization (19). 
Urine concentrations were reported for the following compounds: caffeine (1,3,7-
trimethylxanthine, 137X); paraxanthine (1,7-dimethylxanthine, 17X); theobromine (3,7-
dimethylxanthine, 37X); theophylline (1,3-dimethylxanthine, 13X); 1,3,7-trimethyluric acid 
(137U); 1,3-dimethyluric acid (13U); 1,7-dimethyluric acid (17U); 1-methyluric acid (1U); 
1-methylxanthine (1X); 3,7-dimethyluric acid (37U); 3-methyluric acid (3U); 3-
methylxanthine (3X); 7-methyluric acid (7U); 7-methylxanthine (7X); 5-acetylamino-6-
amino-3-methyluracil (AAMU). AAMU is the decomposition product of the relatively 
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unstable caffeine metabolite 5-acetylamino-6-formylamino-3-methyluracil (AFMU). 
Samples were treated such that all AFMU was converted to the more stable AAMU. Limits 
of detection (LOD) in urine were as follows: theophylline, theobromine, 1U, 13U, 17U, 
37U, 137U, 1X, 3X, 7X, 13X, 37X: 0.05 μmol/L; caffeine, paraxanthine, AAMU, 3U, 7U: 
0.1 μmol/L (19). Results were reported for caffeine and caffeine metabolites in 2714 
participants (17). All reported results satisfied the requirements of a multi-rule quality 
control system (20) using 3 QC pool concentrations for each analyte. Coefficients of 
variation for the study were ≤5% at analyte concentrations ≥1 μmol/L (21).
Study variables
Spot urine concentrations (μmol/L) and excretion rates (nmol/min) of caffeine and caffeine 
metabolites were used as dependent variables in our analyses. The inclusion of urine flow 
rate data in the NHANES 2009–2010, calculated by dividing the total volume of the urine 
sample collected in the MEC by the total time between the previous urine sample collection 
and the urine sample collected in the MEC, permitted the calculation of urine excretion 
rates. Excretion rates were calculated as the product of the spot urine concentration and the 
urine flow rate (22).
Independent variables consisted of general demographic variables (age, sex, race-ethnicity) 
and caffeine intake. Demographic variables used in the study were categorized as follows: 
sex (male, female); age (6–11 y, 12–19 y, 20–39 y, 40–59 y, ≥60 y); race-ethnicity [Hispanic 
(sum of Mexican-American and other Hispanic), non-Hispanic black (NHB), non-Hispanic 
white (NHW)]. Caffeine intake was calculated as the sum of intake from foods and 
beverages (23), and non-prescription and prescription dietary supplements, as well as non-
prescription antacids that contain calcium and/or magnesium (24) from the 24-h dietary 
recall interview (Day 1) conducted at the MEC as it preceded the MEC urine collection. 
Caffeine intake was used as both a continuous and categorical (quartiles) variable.
Analytic sample
All MEC-examined NHANES 2009–2010 participants ≥6 y with caffeine or caffeine 
metabolite measurements were eligible for inclusion in our study. Individuals who reported 
using in the past 30 d any prescription medications known to inhibit or induce any of the 
enzyme systems involved in caffeine metabolism (n = 246) or were uncertain about their use 
of prescription medications (n = 2) were excluded because of potential spurious effects on 
analyte concentrations and excretion rates (Supplemental Table 1). We used pairwise 
deletion for missing values in a particular analysis and verified using Little’s test [25] that 
these deletions would not introduce any biases. Based on these criteria urine concentration 
data were available for 2466 participants and excretion rate data were available for 2261 
participants. (Supplemental Table 2).
Statistical methods
Statistical analyses were performed using SAS (version 9, SAS Institute Inc., Cary, NC) and 
SUDAAN (version 9.2, RTI, Research Triangle Park, NC) software. MEC examination 
weights were used to account for differential nonresponse or non-coverage and to adjust for 
oversampling. Urine concentration and excretion rate distributions were highly right-
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skewed; consequentially, geometric means were used instead of arithmetic means. Bivariate 
associations for categorical variables were described by presenting geometric means and 
selected percentiles with 95% CIs. Geometric means were compared across categories by 
use of Wald F tests which assess whether at least one of the means across the categories is 
significantly different from the others, or pairwise t-tests. Spearman correlation was used to 
describe bivariate association between urine concentration or excretion rate and caffeine 
intake. We did not perform any adjustments for multiple comparisons as the primary 
objective of our study was descriptive and not to test a particular hypothesis.
Results
Detection by use of LC-MS/MS
We found that the detection rates for urine caffeine and caffeine metabolites in the NHANES 
2009–2010 cycle ranged from 80.2% to 100% (Supplemental Table 3). One-third of the 
compounds measured were detected in either 100% (1U, 1X) or ≥99% (3X, 7X, 37X) of 
study samples. The lowest detection rates among analytes included caffeine (91%), 137U 
(88%) and 3U (80%).
Total population
We calculated geometric mean, median and central 95% reference interval (i.e. 2.5th and 
97.5th percentiles) concentrations for caffeine and its metabolites in spot urine samples 
(Table 1; excretion rate data is presented in Supplemental Table 4). Caffeine and its 
metabolites were present in the urine of most persons at concentrations ≥1 μmol/L for a 
majority of analytes. The highest geometric mean and median spot urine concentrations and 
excretion rates were observed for 1U, and the lowest concentrations and excretion rates were 
observed for 3U. Geometric mean spot urine concentrations (95% CI) across all analytes 
ranged from 0.539 (0.492–0.590) μmol/L to 54.1 (48.7–60.0) μmol/L, and median 
concentrations ranged from 0.560 (0.497–0.620) μmol/L to 58.6 (48.6–67.2) μmol/L. 
Analytes in descending order of concentration central tendency (median) were as follows: 
1U > 7X > AAMU > 3X > 1X > 17U > theobromine > 7U > paraxanthine > 13U > caffeine 
> theophylline > 137U > 37U > 3U. Geometric mean excretion rates across all analytes 
ranged from 0.390 (0.357–0.426) nmol/min to 39.4 (35.8–43.4) nmol/min, and median 
excretion rates ranged from 0.423 (0.385–0.468) nmol/min to 46.0 (40.7–50.2) nmol/min. 
With the exception of AAMU and 7X, the descending order of excretion rate central 
tendency was identical to that observed with concentration (1U > AAMU > 7X > 3X > 1X > 
17U > theobromine > 7U > paraxanthine > 13U > caffeine > theophylline > 137U > 37U > 
3U).
Demographic variables
We determined geometric mean spot urine concentrations of caffeine and caffeine 
metabolites stratified by sex and race-ethnicity (Table 2; excretion rate data appear in 
Supplemental Table 5) and by age categories (Table 3; excretion data appear in 
Supplemental Table 6). Higher geometric mean concentrations were observed in men vs. 
women for 1X, 1U (Wald F P <0.01), paraxanthine, and AAMU (Wald F P <0.05). 
Geometric mean excretion rates were higher in men vs. women for 1X, 1U, 13U, AAMU 
Rybak et al. Page 5
J Nutr. Author manuscript; available in PMC 2017 December 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(Wald F P <0.0001), paraxanthine (Wald F P <0.001), theophylline, 17U, and 7X (Wald F P 
<0.01). No statistically significant cases were observed where urine concentrations or 
excretion rates were higher in women vs. men. Geometric mean concentrations and 
excretion rates for all compounds were higher in NHW vs. Hispanics and NHB (1.6–3.4× 
and 1.3–2.6×, respectively; Wald F P ≤ 0.0001 in all cases). Geometric mean concentrations 
were highest in persons aged 40–59 y and lowest in persons aged 6–11 y for caffeine, 
paraxanthine, theophylline, 1X, 1U, 13U, 17U, 137U, and AAMU. Geometric mean 
excretion rates showed the same behavior with age for the same analytes plus 3X, 3U, 7U 
and 37U.
Caffeine intake
We calculated Spearman correlations of spot urine caffeine and caffeine metabolite 
concentration with caffeine intake, and geometric mean concentrations by intake quartiles 
(Table 4; excretion rate data appear in Supplemental Table 7). We found that dietary intake 
was a significant correlate of both concentration and excretion rate. Spot urine 
concentrations were weakly to moderately correlated with caffeine intake (Spearman |r| 
0.15–0.63, P <0.0001). The overall range of correlations observed with excretion rate was 
similar (|r| 0.24–0.68 P <0.0001) and the individual correlation coefficients were also similar 
(difference <0.10) to those noted with urine concentrations. We observed that the 
correlations appeared to fall into two distinct ranges (illustrated in Figure 1 in relation to 
caffeine metabolism). The group of compounds in the higher range (identified herein as 
“Group 1” (0.55 ≤ |r| ≤ 0.68), consisted of caffeine, three of its metabolites (paraxanthine, 
theophylline, and 137U), and 5 subsequent metabolites of paraxanthine and/or theophylline 
(17U, AAMU, 1X, 1U, and 13U). The group of compounds in the lower range (identified 
herein as “Group 2”, 0.15 ≤ |r| ≤ 0.33) consisted of theobromine, 37U, and the remaining 3- 
and 7-monomethyl xanthines and uric acids (3X, 7X, 3U, 7U).
We found that geometric mean concentrations and excretion rates increased with increasing 
quartiles of caffeine intake for all compounds (trend P <0.0001). For the Group 1 
compounds, strong trends were observed for both geometric mean concentrations and 
excretion rates with increasing quartiles of caffeine intake, and all differences among 
quartiles were significant (pairwise t-test P < 0.0001) (Supplemental Table 8). For these 
compounds we observed a large difference between the highest quartile of intake vs. the 
lowest for geometric mean concentrations (6–19×) and excretion rates (9–27×). By 
comparison, for the Group 2 compounds we observed a smaller difference between the 
highest vs. lowest quartiles of caffeine intake for geometric mean concentrations (2–3×) and 
excretion rates (3–4×). Differences in geometric mean concentrations between the second 
and third intake quartiles for these compounds were non-significant (pairwise t-test P = 
0.10–0.95) and differences among mean excretion rates ranged from significant to non-
significant (pairwise t-test P = 0.0013–0.08).
Correlation among analytes
We calculated Spearman correlations among spot urine concentrations and excretion rates of 
caffeine and caffeine metabolites (Supplemental Tables 9 and 10, respectively). A high 
degree of correlation was observed among analytes for both concentration and excretion 
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rate. Approximately 40% of the possible correlations had Spearman |r| ≥0.8, 25% of which 
were ≥0.9. In the case of excretion rate, nearly half of the correlations had |r| ≥0.8, 30% of 
which were ≥0.9. All inter-analyte correlations ≥0.8 occurred within either Group 1 or 
Group 2; we did not observe a single correlation of ≥0.8 between a Group 1 and Group 2 
compound with either urine concentration or excretion rate.
Discussion
This study presents urine concentrations and excretion rates for caffeine and caffeine 
metabolites in the U.S. population aged ≥6 y (NHANES 2009–2010) in the context of age, 
sex, race- ethnicity, and caffeine intake. Based on their correlations with caffeine intake, we 
identified 2 apparent groups of biomarkers: Group 1 with moderate and Group 2 with weak 
correlations (Figure 1). The Group 1 compounds had among the highest detection rates, 
concentrations, and excretion rates of all compounds examined in our study, and exhibited 
patterns that were generally consistent with caffeine intake when stratified by age, sex and 
race-ethnicity. These favorable characteristics support their consideration as potential 
biomarkers of caffeine intake.
Although spot urine samples do not represent quantitative recovery and inter-individual 
differences in metabolism exist, the high detection rates, concentrations, and excretion rates 
we observed for the Group 1 paraxanthine metabolites (1U, 1X and AAMU) seem consistent 
with what is known regarding caffeine metabolism. Paraxanthine is the main pathway for 
caffeine metabolism in humans (72%) and is rarely encountered as a dietary compound 
while theobromine (20%) and theophylline (8%) are less prominent products of caffeine 
metabolism (26). Paraxanthine metabolites may therefore deserve special consideration as 
potential biomarkers of caffeine intake.
Most caffeine is expected to be recovered in the urine as 1U (26.5%), followed by 1X 
(19%), AFMU (16%), 7X (7.5%), paraxanthine (6.5%), 17U (6%) and 3X (3%) (26). The 
production and clearance of AFMU (measured as AAMU in our analyses) behaves in 
tandem with 1U and 1X due to the believed existence of a common precursor (27). The 
relatively high concentrations and excretion rates we observed for 3X and 7X, however, 
suggest that contributions from dietary theophylline and theobromine are also present. Both 
theophylline and theobromine are recovered in the urine as 3X (14%, 21.5%, respectively) 
and theobromine also contributes to the appearance of 7X (36%) (26). Our finding of a near 
ubiquitous presence of caffeine metabolites in the urine, particularly those produced via 
paraxanthine metabolism (1U, AAMU, 1X, 17U, 17X) appears to be consistent with a high 
prevalence of caffeine consumption in the U.S. population, with 87% of the U.S. population 
(28) and 73% of children (2) consuming caffeine on a given day. Interestingly, our detection 
of AAMU and 17U at the 2.5th percentile implies that caffeine intake may be under-
reported, since AAMU and 17U are produced exclusively via paraxanthine and dietary 
exposure to paraxanthine is virtually nonexistent (26).
Caffeine intake in the U.S. tends to follow an inverted U-shape age pattern with intake 
highest in persons aged 40–59 (1), higher in males vs. females (1,25), and higher in NHW 
vs. NHB and Hispanics/Mexican-Americans (1). We observed many cases where compound 
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concentrations and excretion rates showed patterns with age, sex and race-ethnicity 
analogous to those seen with intake (illustrated in Figure 2, using AAMU as an example). 
We found that these similarities occurred more frequently in compounds most correlated 
with dietary intake (Group 1) and with excretion rate data. The association of age, sex, and 
race-ethnicity with caffeine metabolism is not straightforward; however, there is some 
evidence suggesting that these demographic factors may have limited influence on 
biomarker behavior. Age has been shown in males to have no significant effect on peak 
plasma concentration, time to reach peak concentration, or half-life of caffeine metabolites 
(29,30), although urine excretion of 17U, 1U and 7U was statistically higher in older 
subjects (31). No sex-based differences in caffeine metabolism have been observed based on 
urine metabolites and metabolite ratios (32), although CYP1A2 activity, which affects 
multiple stages of caffeine metabolism, has been shown to be higher in men vs. women (33).
Our findings appear to be consistent with other urine biomarker studies (10,11). Crews et al. 
(10) performed a caffeine dosing study with 8 volunteers of known CYP1A2 phenotypes in 
which 24-h urines were collected and analyzed for caffeine, paraxanthine, 1X, 17U, and 
AFMU. Correlations with caffeine dose (r, not specified but presumed to be Pearson 
correlation) were 0.76–0.93 for all subjects, and 0.77–0.95 by CYP1A2 phenotype. In our 
study, excretion rates for paraxanthine, 17U and 1X showed similar promise as intake 
biomarkers based on their high detection frequency (>95%), correlation with intake (|r| = 
0.62–0.66) and concordant patterns with demographic variables. Although not directly 
comparable, the higher correlations observed by Crews et al. are likely a result of their 
controlled experimental design in which 24-hour urines were collected, and diet, caffeine 
dosing, and urine collection timing were regulated, whereas the NHANES is limited to self-
reported dietary intake data on individuals consuming their normal diets, and a spot urine 
sample collected at varying times relative to caffeine consumption. AFMU was dismissed as 
a potential biomarker by Crews et al. due to compound stability and analysis issues, and 1U 
was not evaluated as a biomarker candidate; however, in our study the excretion rates for 
these two compounds also showed demonstrably high detection frequency (> 97%), 
correlation with intake (|r| 0.65–0.67), and consistent demographic trends. In another study, 
Grosso et al. (11) et al. studied the correlation of spot urine caffeine, paraxanthine, 
theophylline, and theobromine concentrations with both average and 24-h caffeine intake in 
pregnant women (n = 98–263) at various times throughout pregnancy. They observed 
correlations in pregnant women similar to what we found in a representative sample of the 
U.S. population. Spearman correlations for urine caffeine, paraxanthine and theophylline 
were 0.50–0.66 with average intake and 0.46–0.71 with 24-h intake depending on the 
analyte and timeframe (P <0.0001); all correlations with urine theobromine were <0.2 and 
most often non-significant (P >0.05).
We believe that our study has 2 key strengths: it is the first to describe urine caffeine and 
caffeine metabolite concentrations and excretion rates in a diverse, representative population 
subset in relation to age, sex, and race-ethnicity; and it is the first to examine the relationship 
of urine caffeine metabolites with caffeine intake to identify potential intake biomarkers 
using spot urine samples from a representative population subset. We do acknowledge, 
however, that there are limitations to our study and that while our findings are promising 
further work is needed. Cross-sectional data has many sources of variability that are absent 
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from more controlled study designs such as the dosing study performed by Crews et al. (10). 
We did not account for physiologic (e.g., fasting time, kidney and liver function) and 
lifestyle (e.g., exercise, smoking status, alcohol use) variables that may affect caffeine 
pharmacokinetics. Future study of these variables to gain an understanding of their 
association with potential caffeine biomarkers would be prudent. The caffeine intake data we 
used from the NHANES also has its limitations. Although dietary intake data was collected 
during an interview by highly trained personnel using a well-validated dietary recall 
instrument (USDA Automated Multi-Pass Method) (34), the presence of inaccuracies—
underestimations in particular—is possible due to challenges in identifying and accurately 
establishing the caffeine content of dietary sources or errors made by survey respondents 
during the interview. We included caffeine intake from dietary supplements in our analyses; 
however, caffeine intake from sources such as prescription and non-prescription medications 
was not available in the NHANES. We were able to identify groups of compounds with 
similar characteristics in relation to caffeine intake and rationalize their existence based on 
an understanding of caffeine metabolism; however, the existence of these apparent groups 
was based entirely on perception, and a more objective study using statistical approaches 
such as cluster analyses is warranted. Nonetheless, even with these limitations considered, 
we believe our study provides a unique population based perspective on urine caffeine and 
caffeine metabolite concentrations and excretion rates and serves as a valuable step towards 
identifying and validating compounds that could serve as biomarkers of caffeine intake.
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Figure 1. 
Relationship of caffeine metabolism in humans to correlations observed between spot urine 
caffeine and caffeine metabolite concentrations and excretion rates with 24-h caffeine intake 
from foods and dietary supplements in U.S. persons aged ≥6 y, NHANES 2009–2010. 
“Group 1” consists of compounds for which Spearman correlations of 0.55 ≤ |r| ≤ 0.68 with 
intake were observed; “Group 2” consists of compounds for which Spearman correlations of 
0.15 ≤ |r| ≤ 0.33 with intake were observed (Table 4, Supplemental Table 7). 137U, 1,3,7-
trimethyluric acid; 13U, 1,3-dimethyluric acid; 17U, 1,7-dimethyluric acid; 1U, 1-
methyluric acid; 1X, 1-methylxanthine; 37U, 3,7-dimethyluric acid; 3U, 3-methyluric acid; 
3X, 3-methylxanthine; 7U, 7-methyluric acid; 7X, 7-methylxanthine; AAMU, 5-
acetylamino-6-amino-3-methyluracil.
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Figure 2. 
Comparison of 24-h caffeine intake from diet and supplements, spot urine 5-acetylamino-6-
amino-3-methyluracil (AAMU) concentrations, and urine AAMU excretion rates s in U.S. 
persons aged ≥6 y, NHANES 2009–2010, stratified by demographic variables. Values are 
medians ± 95% CI. (A) caffeine intake, (B) AAMU concentration, and (C) AAMU excretion 
rate stratified by age. (D) caffeine intake, (E) AAMU concentration, and (F) AAMU 
excretion rate stratified by sex. (G) caffeine intake, (H) AAMU concentration, and (I) 
AAMU excretion rate stratified by race-ethnicity. M, male; F, female; NHW, non-Hispanic 
white; NHB, non-Hispanic black. Sample sizes (n) for spot urine concentration and 
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excretion rate data appear in Supplemental Table 2. Intake data sample sizes were as 
follows: Age: 6–11 y, n = 358; 12–19 y, n = 381; 20–39 y, n = 575; 40–59 y, n = 589; ≥60 y, 
n = 505; Sex: male, n = 1178; female, n = 1230; Race-ethnicity: non-Hispanic white, n = 
1028; non-Hispanic black, n = 447; all Hispanic, n = 807.
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